tetano
Editor, Senior Moderator
Microbiol Immunol. 2014 Nov 14. doi: 10.1111/1348-0421.12210. [Epub ahead of print]
Consecutive oral administration of Bifidobacterium longum MM-2 improves the defense system against influenza virus infection by enhancing natural killer cell activity in a murine model.
Kawahara T1, Takahashi T, Oishi K, Tanaka H, Masuda M, Takahashi S, Takano M, Kawakami T, Fukushima K, Kanazawa H, Suzuki T.
Author information
Abstract
Bifidobacterium, one of the major intestinal microflora components, shows anti-influenza virus (IFV) potential as a probiotic, partly through enhancement of innate immunity from modulation of the intestinal immune system. We isolated Bifidobacterium longum MM-2 (MM-2), a very safe bacterium in humans, from healthy humans. Here, we show the protective effect of MM-2 against IFV infection in a murine model. In mice that had been intranasally inoculated with IFV, consecutive oral administration of MM-2 improved clinical symptoms, reduced mortality, suppressed inflammation in the lower respiratory tract, and decreased virus titers, cell death, and pro-inflammatory cytokines such as interleukin (IL)-6 and tumor necrosis factor-α in bronchoalveolar lavage fluid. The anti-IFV mechanism of MM-2 involves innate immunity through significant elevations of natural killer (NK) cell activities in the lungs and spleen and a significant increase in pulmonary gene expression levels of NK cell activators such as interferon (IFN)-γ, IL-2, IL-12 and IL-18. MM-2 administration also induced significant enhancement of both IFN-γ production from Peyer's patch cells (PPs) and splenetic NK cell activity, even in non-infected mice. Consecutive oral administration of MM-2 activates systemic immunoreactivity from PPs that contributes to innate immunity including NK cell activation, resulting in an anti-IFV effect. MM-2 may be a benefical probiotic as a prophylactic agent in the management of an IFV epidemic.
This article is protected by copyright. All rights reserved.
KEYWORDS:
Bifidobacterium longum; influenza virus; natural killer cell; probiotics
PMID:
25400245
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25400245
Consecutive oral administration of Bifidobacterium longum MM-2 improves the defense system against influenza virus infection by enhancing natural killer cell activity in a murine model.
Kawahara T1, Takahashi T, Oishi K, Tanaka H, Masuda M, Takahashi S, Takano M, Kawakami T, Fukushima K, Kanazawa H, Suzuki T.
Author information
Abstract
Bifidobacterium, one of the major intestinal microflora components, shows anti-influenza virus (IFV) potential as a probiotic, partly through enhancement of innate immunity from modulation of the intestinal immune system. We isolated Bifidobacterium longum MM-2 (MM-2), a very safe bacterium in humans, from healthy humans. Here, we show the protective effect of MM-2 against IFV infection in a murine model. In mice that had been intranasally inoculated with IFV, consecutive oral administration of MM-2 improved clinical symptoms, reduced mortality, suppressed inflammation in the lower respiratory tract, and decreased virus titers, cell death, and pro-inflammatory cytokines such as interleukin (IL)-6 and tumor necrosis factor-α in bronchoalveolar lavage fluid. The anti-IFV mechanism of MM-2 involves innate immunity through significant elevations of natural killer (NK) cell activities in the lungs and spleen and a significant increase in pulmonary gene expression levels of NK cell activators such as interferon (IFN)-γ, IL-2, IL-12 and IL-18. MM-2 administration also induced significant enhancement of both IFN-γ production from Peyer's patch cells (PPs) and splenetic NK cell activity, even in non-infected mice. Consecutive oral administration of MM-2 activates systemic immunoreactivity from PPs that contributes to innate immunity including NK cell activation, resulting in an anti-IFV effect. MM-2 may be a benefical probiotic as a prophylactic agent in the management of an IFV epidemic.
This article is protected by copyright. All rights reserved.
KEYWORDS:
Bifidobacterium longum; influenza virus; natural killer cell; probiotics
PMID:
25400245
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25400245